 In a regulatory 8-K filing, on June 30, Dare Bioscience Inc NASDAQ: DARE entered into an agreement with the Bill Melinda Gates Foundation for a new grant of up to 48.95 million for DARE-LARC1, its investigational user-controlled, long-acting reversible contraceptive. The Grant will support technology development and preclinical activities to advance DARE-LARC1 toward clinical testing in humans from June 30 to November 1, 2026. 